We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+20.56%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$4.36B
AUM Growth
+$814M
Cap. Flow
+$435M
Cap. Flow %
9.98%
Top 10 Hldgs %
53.12%
Holding
130
New
25
Increased
23
Reduced
18
Closed
26

Top Buys

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$183M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$135M
3
ATNX
Athenex, Inc. Common Stock
ATNX
+$65.5M
4
NVRO
NEVRO CORP.
NVRO
+$44.9M
5
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$37.8M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$89.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$76.6M
3
NVTA
Invitae Corporation
NVTA
+$17.6M
4
IRTC icon
iRhythm Holdings
IRTC
+$15M
5
ZGNX
Zogenix, Inc.
ZGNX
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Financials 0.76%
3 Technology 0.14%
4 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
26
ADMA Biologics
ADMA
$2.02B
$44.6M 1.02%
11,521,102
+5,000,000
+77% +$22.1M
ALLO icon
27
Allogene Therapeutics
ALLO
$625M
$41.5M 0.95%
1,543,790
– –
VRCA icon
28
Verrica Pharmaceuticals
VRCA
$89M
$39.6M 0.91%
341,041
– –
KOD icon
29
Kodiak Sciences
KOD
$2.5B
$36.7M 0.84%
3,135,199
– –
MNTA
30
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$36.2M 0.83%
2,905,000
+30,000
+1% +$398K
ONCE
31
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$35.8M 0.82%
+350,000
New +$37.8M
CTMX icon
32
CytomX Therapeutics
CTMX
$690M
$35.4M 0.81%
3,153,923
-20,000
-0.6% -$210K
EHTH icon
33
eHealth
EHTH
$41.9M
$33.2M 0.76%
385,982
+96,125
+33% +$6.47M
VAPO
34
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$32.3M 0.74%
175,559
+19,770
+13% +$2.93M
NVTA
35
DELISTED
Invitae Corporation
NVTA
$31.6M 0.72%
1,343,491
-828,427
-38% -$17.6M
NEPT
36
DELISTED
Neptune Wellness Solutions Inc. Ordinary Shares
NEPT
$30M 0.69%
6,351
– –
DBVT
37
DBV Technologies
DBVT
$813M
$29.7M 0.68%
360,908
+248,056
+220% +$22.2M
RCKT icon
38
Rocket Pharmaceuticals
RCKT
$343M
$29.7M 0.68%
1,977,412
+1,519,239
+332% +$26.5M
ESTA icon
39
Establishment Labs
ESTA
$2.71B
$27.7M 0.64%
1,260,528
+646,286
+105% +$15.4M
CBAY
40
DELISTED
Cymabay Therapeutics
CBAY
$27.7M 0.63%
3,862,821
-350,000
-8% -$3.96M
KDMN
41
DELISTED
Kadmon Holdings, Inc.
KDMN
$27.1M 0.62%
13,165,746
– –
CNCE
42
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$26.5M 0.61%
2,204,641
– –
VBIV
43
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$24.6M 0.56%
865,052
+66,667
+8% +$3.61M
SLDB icon
44
Solid Biosciences
SLDB
$792M
$22.6M 0.52%
+261,815
New +$28.6M
QURE icon
45
uniQure
QURE
$2.75B
$22M 0.51%
281,820
+50,000
+22% +$3.19M
EIDX
46
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$21.3M 0.49%
686,992
– –
TDOC icon
47
Teladoc Health
TDOC
$1.66B
$20.4M 0.47%
307,021
-187,979
-38% -$11M
STOK icon
48
Stoke Therapeutics
STOK
$1.84B
$19.6M 0.45%
+671,978
New +$18M
ALDX icon
49
Aldeyra Therapeutics
ALDX
$97.1M
$18.5M 0.42%
3,085,458
– –
TPTX
50
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$17.3M 0.4%
+424,968
New +$15.2M
1
2
3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q2 2019 Portfolio in Review

As of Q2 2019, Perceptive Advisors held 130 positions worth $4.36B, up 23% from $3.54B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $435M of net new capital in Q2 2019, opening 25 new positions and adding to 23 existing holdings. Its largest new stake was BridgeBio Pharma: 6,706,268 shares worth $181M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $89.6M trimmed.

  • Perceptive Advisors's largest Q2 2019 buy was BridgeBio Pharma: 6,706,268 shares worth $181M.
  • Perceptive Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2019, an estimated $135M increase.
  • Perceptive Advisors's biggest Q2 2019 reduction was Array Biopharma Inc, cutting an estimated $89.6M.
  • Perceptive Advisors fully exited iRhythm Holdings in Q2 2019, selling an estimated $15M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $4.36B portfolio in Q2 2019.
  • Perceptive Advisors opened 25 new positions and closed 26 in Q2 2019.
  • Perceptive Advisors's portfolio value rose 23% quarter-over-quarter to $4.36B.

Based on Perceptive Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.